{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:46:15Z","timestamp":1791895575511,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3\u20135\u2009years, we estimated the effectiveness of administering a two-dose schedule, 28\u2009days apart, of Sinovac\u2019s inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5\u201339.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6\u201375.2) against hospitalization and 69.0% (95% CI, 18.6\u201388.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3\u20135\u2009years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.<\/jats:p>","DOI":"10.1038\/s41591-022-01874-4","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T12:06:39Z","timestamp":1653307599000},"page":"1377-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Effectiveness of CoronaVac in children 3\u20135 years of age during the SARS-CoV-2 Omicron outbreak in Chile"],"prefix":"10.1038","volume":"28","author":[{"given":"Alejandro","family":"Jara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-1253","authenticated-orcid":false,"given":"Eduardo A.","family":"Undurraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Zubizarreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Soto-Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Gilabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Leighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Eguiguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heriberto","family":"Garc\u00eda-Escorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-0626","authenticated-orcid":false,"given":"Rafael","family":"Araos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"1874_CR1","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/"},{"key":"1874_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533\u2013534 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1874_CR3","doi-asserted-by":"crossref","unstructured":"Madhi, S. A. et al. Population immunity and Covid-19 severity with Omicron variant in South Africa. N. Engl. J. Med. 386, 1314\u20131326 (2022).","DOI":"10.1056\/NEJMoa2119658"},{"key":"1874_CR4","doi-asserted-by":"crossref","unstructured":"Cloete, J. et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. Lancet Child Adolesc. Health 6, 294\u2013302 (2022).","DOI":"10.1016\/S2352-4642(22)00027-X"},{"key":"1874_CR5","doi-asserted-by":"crossref","unstructured":"Altarawneh, H. N. et al. Protection against the Omicron variant from previous SARS-CoV-2 infection. N. Engl. J. Med. 386, 1288\u20131290 (2022).","DOI":"10.1056\/NEJMc2200133"},{"key":"1874_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 185, 447\u2013456 (2022).","journal-title":"Cell"},{"key":"1874_CR7","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. COVID infection severity in children under 5 years old before and after Omicron emergence in the US. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2022.01.12.22269179v1 (2022).","DOI":"10.1101\/2022.01.12.22269179"},{"key":"1874_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.15585\/mmwr.mm7104e4","volume":"71","author":"AD Iuliano","year":"2022","unstructured":"Iuliano, A. D. et al. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods\u2014United States, December 2020\u2013January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 146\u2013152 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1874_CR9","first-page":"e1","volume":"107","author":"P Zimmermann","year":"2021","unstructured":"Zimmermann, P., Pittet, L. F., Finn, A., Pollard, A. J. & Curtis, N. Should children be vaccinated against COVID-19? Arch. Dis. Child 107, e1 (2021).","journal-title":"Arch. Dis. Child"},{"key":"1874_CR10","unstructured":"Coronavirus Vaccine Tracker. The New York Times. https:\/\/nyti.ms\/3nvAEc4"},{"key":"1874_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","volume":"386","author":"EB Walter","year":"2022","unstructured":"Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 386, 35\u201346 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1874_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa2117995","volume":"386","author":"SM Olson","year":"2022","unstructured":"Olson, S. M. et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N. Engl. J. Med. 386, 713\u201323. (2022).","journal-title":"N. Engl. J. Med."},{"key":"1874_CR13","doi-asserted-by":"publisher","unstructured":"Dorabawila, V. et al. Risk of Infection and Hospitalization Among Vaccinated and Unvaccinated Children and Adolescents in New York After the Emergence of the Omicron Variant. JAMA https:\/\/doi.org\/10.1001\/jama.2022.7319 (2022).","DOI":"10.1001\/jama.2022.7319"},{"key":"1874_CR14","doi-asserted-by":"crossref","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. Preprint at https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4035405 (2021).","DOI":"10.2139\/ssrn.4035405"},{"key":"1874_CR15","doi-asserted-by":"crossref","unstructured":"Gonzalez, S. et al. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2022.04.18.22273978v1 (2022).","DOI":"10.2139\/ssrn.4087375"},{"key":"1874_CR16","doi-asserted-by":"crossref","unstructured":"Collie, S., Champion, J., Moultrie, H., Bekker, L.-G. & Gray, G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N. Engl. J. Med. 386, 494\u2013496 (2022).","DOI":"10.1056\/NEJMc2119270"},{"key":"1874_CR17","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022)."},{"key":"1874_CR18","doi-asserted-by":"crossref","unstructured":"Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088\u20131091 (2022).","DOI":"10.1056\/NEJMc2119912"},{"key":"1874_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944 (2022).","journal-title":"Lancet"},{"key":"1874_CR20","unstructured":"Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine. https:\/\/bit.ly\/3J3GZHc (2021)."},{"key":"1874_CR21","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","volume":"10","author":"A Jara","year":"2022","unstructured":"Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob. Health 10, e798\u2013e806 (2022).","journal-title":"Lancet Glob. Health"},{"key":"1874_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875\u2013884 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1874_CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life\u2010tables. J. R. Stat. Soc. Ser. B Stat. Methodol. 34, 187\u2013202 (1972).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"1874_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins, J. M., Hernan, M. A. & Brumback, B. Marginal structural models and causal inference in epidemiology. Epidemiology 11, 550\u2013560 (2000).","journal-title":"Epidemiology"},{"key":"1874_CR25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole, S. R. & Hern\u00e1n, M. A. Constructing inverse probability weights for marginal structural models. Am. J. Epidemiol. 168, 656\u2013664 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"1874_CR26","doi-asserted-by":"crossref","unstructured":"Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, 2000).","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"1874_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2107058","volume":"385","author":"MG Thompson","year":"2021","unstructured":"Thompson, M. G. et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N. Engl. J. Med. 385, 320\u2013329 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1874_CR28","unstructured":"Therneau, T. M. A Package for Survival Analysis in R. Version 3.3-1. https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html"},{"key":"1874_CR29","unstructured":"The R Project for Statistical Computing. https:\/\/www.r-project.org\/"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01874-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01874-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01874-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:40:58Z","timestamp":1727278858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01874-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01874-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1440357\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A. participated in an online, international advisory board organized by AstraZeneca on 21 March 2022.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}